Isomorphic Labs raises $600M in first external round to tackle AI drug design
Mar 31, 2025
Key Points
- Isomorphic Labs raises $600 million in its first external round, with Thrive Capital leading and Google Ventures co-investing in the Alphabet-backed AI drug-design company.
- Alphabet is outsourcing commercialization pressure to external investors, betting that venture-backed discipline will force Isomorphic to hit product milestones and close customer deals faster than an internally funded lab.
- Isomorphic's partnerships with Eli Lilly and Novartis target multiple therapeutic areas, aiming to prove AI can reduce real cost centers in drug development—a test AlphaFold's protein-folding breakthrough never had to pass.
Summary
Isomorphic Labs, the AI drug-design subsidiary of Alphabet spun out by DeepMind founder Demis Hassabis, raised $600 million in its first external funding round. Thrive Capital led the investment, with participation from Google Ventures. The London-based company will use the capital to advance its AI research and expand its team across multiple therapeutic areas.
The $600 million round is 12 to 40 times larger than the average UK funding round at this stage and equivalent to more than a quarter of all UK life sciences VC investment in 2024, a year in which all UK life sciences companies raised just $2 billion combined.
Alphabet's shift
Isomorphic remains a subsidiary of Alphabet, but the decision to seek substantial external capital signals a strategic shift. Research-heavy companies that thrive under Alphabet's unlimited funding model tend to struggle with commercialization. External investors and board pressure create urgency to hit milestones, close customer deals, and deliver measurable traction in ways an internal lab subsidized indefinitely never needs to prioritize. The venture-backed funding cycle, where companies raise money to hit a specific milestone within 12 to 24 months and then raise again, has proven effective at forcing product discipline in technology development. Alphabet is outsourcing that pressure.
Google likely retains 50% ownership or more as the original builder and funder, though the new round has diluted that stake and created direct equity exposure for employees and founders.
The AlphaFold lesson
Hassabis and his team at DeepMind built AlphaFold, which solved the protein-folding problem. When AlphaFold launched, biotech stocks barely moved. Protein folding, while mathematically impressive, is not a major cost center in drug development. Labs could already afford to outsource the work or hire someone to do it. Solving the problem did not unlock a new class of drugs or accelerate timelines in ways that moved markets.
The gap between AI breakthroughs in isolation and AI breakthroughs that move drug economics is real. Isomorphic's bet is broader. The company has partnerships with Eli Lilly and Novartis and is targeting multiple therapeutic areas simultaneously rather than betting on a single modality or disease. Hassabis has framed the ambition as solving all disease with AI, but execution will require proving that AI can reduce the actual cost centers in drug development: human labor, time to clinical trials, failure rates, or regulatory friction.
Open questions
Isomorphic's post-round valuation, current revenue, customer pipeline depth, and specific therapeutic priorities remain undisclosed. Hassabis's statement that the funding will turbocharge development of the next generation AI drug design engine is optimistic but lacks specifics about what models, approaches, or near-term milestones the company is targeting.